UC Davis Clinical and Translational Science Center
加州大学戴维斯分校临床和转化科学中心
基本信息
- 批准号:8112223
- 负责人:
- 金额:$ 30.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-09 至 2011-09-08
- 项目状态:已结题
- 来源:
- 关键词:AttentionBiological SciencesCaliforniaCenter for Translational Science ActivitiesClinicalClinical ResearchCollaborationsCommunitiesCountryDevelopmentDoctor of PhilosophyEducationEnvironmentEvaluationFacultyFellowshipGoalsGrantHealthcare SystemsHome environmentLeadershipLinkMedicalPhasePopulation HeterogeneityPrincipal InvestigatorResearch PersonnelResourcesScienceServicesSolutionsStructureTechnologyTestingTrainingTranslational ResearchTrustUniversitiescatalystcollegedesignflexibilitypatient oriented researchprograms
项目摘要
he University of California, Davis (UC Davis) is proposing to create a Clinical and Translational Science
Center (CISC) which will transform our medical researchenterprise into a highly jeffective "open"academic
home for clinical and translational research by building on three key assets: 1) Our long-standing
commitment as a land-grant university to serve the geographically disperse and ethnically diverse
populations of inland and Northern California with a health care system enabled by one of the broadest and
most extensivetelecommunications programs in the world; 2) The collaborative culture of UC Davis, which
has one of the most extensive and interdisciplinary life science environments in the country, and 3) An
established CSTC pilot facility - the UCDavis Clinical Research Investigator Services Program (CRISP) that
serves as the physicalhome for clinical and translational researchand for faculty training andcareer
development. CRISP is a fundamentally important CTSC testing ground, where many perceived CTSA
barriers have been explored and solutions tested, and through CRISP, we have completed the planning
phase for the CTSC. In the organizationalstructure of the UC Davis CTSC, considerable attention is paid to
create an organization that is: 1) responsive and familiar to investigators; 2) flexible; 3) well linked to
university leadership, to participating academic units, andto the community; and 4) focused on the goal of
reducing barriers and facilitating the translation of research gains into medical practice. Key featuresare:
Education program focused on "team science"; Extensive collaborations across UC Davis colleges and
centers; Introduction of catalyst functions such as CollaborativeResearch Facilitators andtranslational
postdoctoral fellowships; Dissemination through tele-technology; Flexible use of resources for patient-
oriented research; and a Community engagement program emphasizing trust and respect. The CTSC is
under the leadership of two co-Principal Investigators, Drs. Berglund MD, PhD, (P.I.) and Joseph MD,PhD
(co-P.I.), supportedby a team of Directors and co-Directorsoverseeing each of the 9 CTSC programs, and a
comprehensive committee structure, designed to firmly anchor the CTSC with institutional leadership,
faculty, trainees and the community. The UC Davis CTSC will be implemented through a carefully designed,
collaborative plan, and the activity will be guided through continuous evaluations and corrections.
加州大学戴维斯分校(加州大学戴维斯分校)提议创建临床和转化科学
中心(CISC)将把我们的医学研究人员转变为高度杰出的“开放”学术
通过建立三个关键资产的临床和转化研究之家:1)我们的长期存在
作为一所提供土地授予大学的承诺,为地理上分散和种族多样化服务
内陆和北加州的人口,由最广泛和最广泛的医疗保健系统实现
世界上大多数扩展的eCommunications计划; 2)加州大学戴维斯分校的协作文化
拥有该国最广泛,最跨学科的生活科学环境之一,3)
已建立的CSTC试点设施 - UCDAVIS临床研究研究者服务计划(CRISP)
作为临床和翻译研究的物理霍姆,用于教师培训和护理者
发展。 CRISP是一个根本重要的CTSC测试领域,许多人认为CTSA
已经探索了障碍并测试了解决方案,并且通过Crisp,我们完成了计划
CTSC的阶段。在UC Davis CTSC的组织结构中,非常关注
创建一个是:1)调查人员敏感且熟悉的组织; 2)灵活; 3)与
大学领导,参与学术单位和社区; 4)专注于目标
减少障碍并促进研究成就转化为医学实践。关键功能:
教育计划的重点是“团队科学”;加州大学戴维斯大学大学的广泛合作
中心;引入催化剂功能,例如Collaborativeresearch促进器和翻译
博士后奖学金;通过电视技术传播;灵活地使用资源来患者 -
定向研究;以及一个社区参与计划,强调信任和尊重。 CTSC是
在两名联合首席调查员的领导下。 Berglund MD博士(P.I.)和Joseph MD,PhD
(Co-p.i。),由董事团队和共同导演组成的9个CTSC计划中的每个人支持,
全面的委员会结构,旨在将CTSC牢固地固定在机构领导下,
教师,学员和社区。 UC Davis CTSC将通过精心设计的,
协作计划,该活动将通过持续的评估和更正来指导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LARS F BERGLUND其他文献
LARS F BERGLUND的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LARS F BERGLUND', 18)}}的其他基金
UC Davis Clinical and Translational Science Center
加州大学戴维斯分校临床和转化科学中心
- 批准号:
9261031 - 财政年份:2016
- 资助金额:
$ 30.58万 - 项目类别:
Frontiers of University Training to Unlock the Research Enterprise (FUTURE)
大学培训前沿以解锁研究事业(未来)
- 批准号:
8917070 - 财政年份:2013
- 资助金额:
$ 30.58万 - 项目类别:
Frontiers of University Training to Unlock the Research Enterprise (FUTURE)
大学培训前沿以解锁研究事业(未来)
- 批准号:
8660565 - 财政年份:2013
- 资助金额:
$ 30.58万 - 项目类别:
Frontiers of University Training to Unlock the Research Enterprise (FUTURE)
大学培训前沿以解锁研究事业(未来)
- 批准号:
8738744 - 财政年份:2013
- 资助金额:
$ 30.58万 - 项目类别:
UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE CENTER
加州大学戴维斯分校临床和转化科学中心
- 批准号:
8365059 - 财政年份:2011
- 资助金额:
$ 30.58万 - 项目类别:
CLINICAL AND TRANSLATIONAL SCIENCE CENTER (CTSC) - TRANSLATIONAL PROGPROGRAM
临床与转化科学中心 (CTSC) - 转化项目
- 批准号:
8357286 - 财政年份:2011
- 资助金额:
$ 30.58万 - 项目类别:
相似国自然基金
分子细胞生物科学与技术发展战略研究(2021-2035)
- 批准号:
- 批准年份:2019
- 资助金额:50 万元
- 项目类别:专项基金项目
谷子雄性不育基因的遗传研究
- 批准号:38900031
- 批准年份:1989
- 资助金额:3.0 万元
- 项目类别:青年科学基金项目
相似海外基金
2023 Physics and Chemistry of Microfluidics Gordon Research Conference and Gordon Research Seminar
2023年微流控物理与化学戈登研究会议暨戈登研究研讨会
- 批准号:
10681683 - 财政年份:2023
- 资助金额:
$ 30.58万 - 项目类别:
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer
不可逆电穿孔 (IRE) 联合 CD40 激动作为胰腺癌原位疫苗治疗
- 批准号:
10718057 - 财政年份:2023
- 资助金额:
$ 30.58万 - 项目类别:
Irvine Summer Institute in Biostatistics and Data Science
尔湾生物统计和数据科学夏季学院
- 批准号:
10368726 - 财政年份:2022
- 资助金额:
$ 30.58万 - 项目类别:
Irvine Summer Institute in Biostatistics and Data Science
尔湾生物统计和数据科学夏季学院
- 批准号:
10599118 - 财政年份:2022
- 资助金额:
$ 30.58万 - 项目类别: